Announcement on the Approval of Clinical Trial Notification for a Subsidiary's Vaccine

Hualan Biological Engineering, Inc.·June 5, 2026·2 pages

✨ AI Summary

Hualan Biological Engineering Co., Ltd. announced that its subsidiary, Hualan Vaccine Co., Ltd., received a clinical trial approval notification for a novel adjuvanted influenza virus split vaccine. This vaccine aims to enhance immune responses, particularly in vulnerable populations such as the elderly. The approval allows the company to proceed with clinical trials, which are essential for future product registration and market entry.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

The company and all members of the board guarantee that the content of the information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Securities Code: 002007
Securities Abbreviation: Hualan Biological
Announcement Number: 2026-024

Recently, Hualan Biological Engineering Co., Ltd. (hereinafter referred to as "the Company") announced that its subsidiary, Hualan Vaccine Co., Ltd. (hereinafter referred to as "Hualan Vaccine"), received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration (Notification No.: 2026LP01706). The relevant information is announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.